Reuters logo
BRIEF-Ligand Pharma reaffirms 2017 revenue guidance between $134 mln and $136 mln
November 14, 2017 / 10:41 PM / a month ago

BRIEF-Ligand Pharma reaffirms 2017 revenue guidance between $134 mln and $136 mln

Nov 14 (Reuters) - Ligand Pharmaceuticals Inc

* Ligand Pharmaceuticals-reaffirmed full-year 2017 revenue guidance of between $134 million and $136 million and adjusted EPS guidance of between $2.95 to $3.00​

* Ligand Pharmaceuticals Inc - ‍currently believes potential royalty revenue growth for 2018 could be in range of 15% to 25% over that of full year 2017​

* Ligand Pharmaceuticals Inc - ‍full-year 2018 corporate gross margin is expected to be in range of 94% to 96%​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below